Paysign, Inc. · NASDAQ:PAYS
Paysign — Oppenheimer 11th Annual Emerging Growth Conference (February 2026)
23 slides from Paysign's conference presentation, Feb 3, 2026
Slide 1: Oppenheimer 11th Annual Emerging Growth Conference
NASDAQ: PAYS Oppenheimer 11th Annual Emerging Growth Conference 02.03.2026
Slide 2: Important Notices: Forward-Looking Statements
Important Notices Forward-Looking Statements This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (“Forward-Looking Statements”). All statements other t
Slide 3: Important Notices: Non-GAAP Financial Information
Important Notices Management’s Use of Non-GAAP Financial Information To supplement Paysign’s financial results presented on a GAAP basis, we use non-GAAP measures that exclude from net income the following cash and non-cash items: interest, taxes, depreciation and amortization and stock-based compen
Slide 4: Putting Payments Into Motion
Putting Payments Into Motion Paysign is a leading provider of patient affordability programs, donor compensation solutions, SaaS engagement and management platforms, and integrated payment processing tailored to the life sciences industries. Our scalable solutions are customized to each client’s goa
Slide 5: Company Overview
Company Overview Paysign was incorporated in 1995 and is headquartered in southern Nevada. For more than 20 years, Paysign has been a trusted partner for major pharmaceutical and healthcare companies, as well as multinational corporations, delivering fully managed programs built to meet their indivi
Slide 6: Company Milestones
Company Milestones ‘Company issued its first pharmaceutical prepaid assistance card. Company entered plasma donor compensation market. The company was listed on NASDAQ under the symbol “TPNL" Company rebranded as Paysign and commenced trading under the symbol “PAYS” Providing services to 480 plasma
Slide 7: Investment Highlights
Investment Highlights fe} alls Financials BRITS Technol echnolo Growth gy Strong cashflow, margin Fast growing, high-margin, Leading proprietary cloud- ‘expansion, and zero debt profitable business with based payments platform predictable recurring revenues Ait) Products and Service and i Leadershi
Slide 8: Paysign at a Glance
Paysign at a Glance ies mee PREE a Quarterly Adjusted EBITDA per Diluted Share ©2022 © 2023 @ 2024 © 2025 Market Cap $257.6M Fully Diluted Shares Outstanding 61.8M 2024 Annual Revenue $58.4M $0.0 TTM Revenue $74.9M | ] 1 l [ Q3 2025 Gross Profit Margin 56.3% i = o i 2024 Fully Diluted EPS $0.07 Quar
Slide 9: 52-Week Stock Price Range
52-Week Stock Price Range Weekly Closing Price January 27, 2025, through January 30, 2026 $9.00 $8.00 $7.00 $6.00 $5.00 $4.17 $4.00 $3.00 $2.00 $1.00 $0.00
Slide 10: Investment by the Numbers
Investment by the Numbers all! 2024 Revenue TTM Revenue UUUU g58.4mM $74.9M TTM Adjusted EBITDA “A Q3 2025 Total Assets $17.4M col) $200.5 Revenue by Segment @ Plasma @ Pharma © other sm9M 00m som - - 022 2022 024 rm Revenue Drivers Cardholder Fees Interchange Annual Revenue S765 s7asem 60M 58:38 sa
Slide 11: Patient Affordability Solutions
Patient Affordability Solutions Powering the Convergence of Fintech and Healthcare Pharmacy Benefit Copay Solutions: This includes the standard copay and voucher programs in the Pharmacy industry, which process claims using the the National Council for Prescription Drug Programs (NCPDP) transmission
Slide 12: Patient Affordability by the Numbers
Patient Affordability by the Numbers High growth business segment. Greater than 100% revenue growth expected in 2025. Pharma Revenue by Quarter Annual Pharma Revenue
Slide 13: Plasma Donor Solutions
Plasma Donor Solutions Powering the Convergence of Fintech and Healthcare Paysign offers donor compensation programs that give our clients the tools they need to streamline their operations while increasing donor retention. Since entering the plasma donor compensation market in 2011, Paysign has bec
Slide 14: Plasma by the Numbers
Plasma by the Numbers *COLLECTING PLASMA IN THE US: ECOSYSTEM ANALYSIS, COST BENCHMARKING & FORECAST TO 2034, Marketing Research Bureau, March 2025
Slide 15: New Product Line: Software as a Service
New Product Line: Software as a Service Plasma STACK is a layered, cloud-based software suite designed for the blood and plasma collection industries. Plasma STACK delivers measurable value by combining donor engagement, operational efficiency, and cost reduction into a single, scalable platform. *P
Slide 16: New Markets Overview
New Markets Overview Additional Market Niches Leverage Paysign Solutions Paysign consistently builds and launches beta programs into niche markets to refine payments infrastructure, collect data, and analyze performance. Other growth strategies into additional markets include integrations, partnersh
Slide 17: 2026 U.S. Open-Loop Prepaid Market
2026 U.S. Open-Loop Prepaid Market Paysign Market Segments Paysign Products Paysign Premier Digital Bank Account Total Prepaid Market $266.7B (36.6%) Paysign GPR Card Financial Services (GPR) CAGR 6%, 2020-2026 Paysign Payroll Card $245.9B (33.7%) Paysign Healthcare Benefit Card Payroll & Benefits i
Slide 18: Financial Highlights
Financial Highlights Income Statement Summary
Slide 19: Analyst Coverage
Analyst Coverage Company Analyst D.A. Davidson & Company Peter Heckman Ladenburg, Thalman & Co. Inc. Jonathan Hickman Maxim Group, Michael Diana iad NASDAQ: PAYS
Slide 20: Resources
Resources About Us - Donating Plasma Home - Marketing Research Bureau Home - Donating Plasma A white building with a flag on it Description automatically generated House Committee on Oversight and Accountability FTC Interim Report – Pharmacy Benefit Managers: Staff Report – The Role of Pharmacy Bene
Slide 21: Leadership Team
Leadership Team Mark Newcomer President & Chief Executive Of Eric Trudeau Chief Compliance Officer . Jeff Baker Chief Financial officer Brad Cunningham Chief Technology Officer Joan Herman EVP, EFT Operations Matt Lanford Chief Payments Officer Cosimo Cambi Chief Operating Officer Ali Ches vp, Marke
Slide 22: Independent Directors
Independent Directors -Former CEO and President of Green Dot Corporation (NYSE: GDOT) -Former CEO of NetSpend (2008-2013); Grew annual revenue from $129M to $35IM, with over 2.4 million cardholder accounts; NetSpend acquired by Total ‘System Services: (NYSE: TSS) for $14B Co-founder, former presiden
Slide 23: Thank you!
Main: 702.453.2221 Toll-Free: 888.522.4810 Investor Relations ir@paysign.com 2615 St. Rose Parkway Henderson, NV 89052 Thank you!
Paysign — Oppenheimer 11th Annual Emerging Growth Conference (February 2026) on 6ix